Details of Disease

General Information of Disease (ID: DISNGQVY)

Disease Name	Muscle spasm
Synonyms	muscle cramps, familial
Disease Class	MB47: Tonus and reflex abnormality
Disease Hierarchy	DISYKSRF: Genetic disease DISNGQVY: Muscle spasm
ICD Code	ICD-11 ICD-11: MB47.3
Disease Identifiers	MONDO ID MONDO_0008022 MESH ID C563563 UMLS CUI C1834708 OMIM ID 158400 MedGen ID 371885 HPO ID HP:0003394 SNOMED CT ID 45352006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cinolazepam	DMDX1ZC	Approved	Small molecular drug	[1]
Cisatracurium	DMUZPJ5	Approved	Small molecular drug	[2]
Decamethonium	DMSBRUW	Approved	Small molecular drug	[3]
Rapacuronium bromide	DMQHB5C	Approved	Small molecular drug	[2]
Rocuronium	DMY9BMK	Approved	Small molecular drug	[2]
THIOCOLCHICOSIDE	DMEPWYA	Approved	Small molecular drug	[2]
Tolperisone	DMA2GHJ	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Eperisone	DM1SMAI	Phase 3	Small molecular drug	[4]
Nabiximols	DMHKJ5I	Phase 3	Small molecular drug	[5]
OS-440	DM27Z1L	Phase 3	NA	[5]
FLX-787	DMQX5UA	Phase 2	NA	[5]
VSN-16R	DMZSAT2	Phase 2	Small molecular drug	[6]
MedChew-1401	DMWY1G7	Phase 1	NA	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	Drug information of Cinolazepam, 2008. eduDrugs.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 006931.
4	ClinicalTrials.gov (NCT02040415) Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients. U.S. National Institutes of Health.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	ClinicalTrials.gov (NCT02542787) Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis.